

Test Indications:**Cystatin C testing is indicated in patients:**

- 1) With atypical muscle mass (e.g. Muscular Dystrophy, prolonged hospitalization or immobilization, amputation, malnourishment, body building (not taking rhGH), etc.)
- 2) On a high-protein diet and/or on creatine supplementation
- 3) With volatile serum creatinine levels and uncertainty in their GFR classification (e.g. classification G3a vs G3b)
- 4) Where there is analytical uncertainty in creatinine results (i.e. interference)

Cystatin C testing is NOT indicated in the following:

- 1) **Patients with hypo- or hyperthyroidism.**
 - **TSH should be verified prior to requesting CysC** as hypothyroid and hyperthyroid patients will have lowered and elevated CysC concentrations, respectively, primarily due to the actions of triiodothyronine (T₃).
 - TSH should be corrected into the normal range for at least two weeks prior to testing CysC.
- 2) **Patients with impaired kidney function and currently taking high-dose corticosteroids or recently tapered from a high dose**
 - Glucocorticosteroids elevate circulating CysC levels via mechanisms independent of renal function.
 - Patients who are on chronic (>2 weeks), low or physiological doses of corticosteroids should not be affected and may benefit from CysC testing
 - A two-week washout period is recommended prior to testing patients coming off a steroid taper.
- 3) **Patients with elevated levels of Growth Hormone**
 - CysC levels will be elevated, independent of renal function
 - Therefore, CysC levels may not be reliable in patients with acromegaly, or those taking recombinant human growth hormone (rhGH)

References:

1. Pierre CC, Marzinke MA, Ahmen SB et al. AACC/NKF Guidance Document on Improving Equity in Chronic Kidney Disease. 2023. *J Appl Lab Med*. 8(4): 789-816.
2. Sze L, Bernays RL, Zwimpfer C et al. Impact of growth hormone on cystatin C. 2013. *Nephron Extra*. 3: 118-124.
3. Wiesli P, Schwegler B, Spinaz AS, et al. Serum Cystatin C is Sensitive to Small Changes in Thyroid Function. *Clin Chim Acta*. 2003. 338(1): 87-90.
4. Bokenkamp A, van Wijk JAE, Lentze ML, et al. Effect of Corticosteroid Therapy on Serum Cystatin C and β 2-Microglobulin Concentrations. *Clin Chem*. 2002. 48: 1123-1126